The Oncology QCARD Initiative: Fostering efficient evaluation of initial real-world data proposals

被引:2
作者
Rivera, Donna R. [1 ]
Eckert, Joy C. [2 ]
Rodriguez-Watson, Carla [2 ]
Lerro, Catherine C. [1 ]
Bertagnolli, Monica M. [3 ]
Hubbard, Rebecca A. [4 ]
Kushi, Lawrence H. [5 ]
Lund, Jennifer L. [6 ]
Schrag, Deborah [7 ]
Wang, Shirley V. [8 ]
Wood, William A. [9 ]
Lee, Jennifer J. [1 ]
Okafor, Cristeen [2 ]
Ghauri, Kanwal [2 ]
Winckler, Susan C. [2 ]
Kluetz, Paul G. [1 ]
机构
[1] US FDA, Oncol Ctr Excellence, Silver Spring, MD 20993 USA
[2] Reagan Udall Fdn Food & Drug Adm, Washington, DC USA
[3] Brigham & Womens Hosp, Alliance Clin Trials Oncol Fdn, Boston, MA USA
[4] Univ Penn, Perelman Sch Med, Dept Biostat Epidemiol & Informat, Philadelphia, PA USA
[5] Kaiser Permanente Northern Calif, Div Res, Oakland, CA USA
[6] Univ North Carolina Chapel Hill, Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA
[7] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
[8] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA
[9] Univ North Carolina Chapel Hill, Div Hematol, Chapel Hill, NC USA
关键词
data quality; fit-for-purpose; observational study design; oncology; real-world evidence; real-world data; QUALITY; RECOMMENDATIONS;
D O I
10.1002/pds.5818
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
PurposeThe oncology quality, characterization, and assessment of real-world data (Oncology QCARD) Initiative was formed to develop a set of minimum study design and data elements needed to evaluate the fitness of the real-world data (RWD) source(s) proposed in an initial study concept as part of early interaction with scientific reviewers.MethodsA multidisciplinary executive committee (EC) was established to guide the Oncology QCARD Initiative. The EC conducted a landscape review of published literature, guidances, and guidelines to evaluate relevant dimensions of data quality measurement. Guided by the review and informed by expert feedback, the Oncology QCARD Initial Protocol Characterization (IPC) provides a summary of minimum elements needed to adequately describe an initial clinical study concept that involves RWD and is intended to support decision-making.ResultsFit-for-use data and fit-for-purpose design emerged as themes from the landscape analysis. Data that are fit-for-use are both relevant (sufficiently capturing exposure, outcomes, and covariates) and reliable (understanding data accrual and quality control and whether the data represent the underlying concepts they are intended to represent) to answer a specific research question. A fit-for-purpose design takes appropriate steps to ensure internal and external validity and allows for transparency in reporting. The QCARD-IPC focuses on high-level characteristics of RWD sources and study design domains including data temporality, population, medical product exposure, comparators, and covariates, endpoints, statistical analysis, and data quality assurance plans.ConclusionsEvaluation of studies including RWD requires understanding the data source, study design, and potential biases to preliminarily evaluate whether selected RWD are fit-for-use for the research question. The Oncology QCARD-IPC provides a structured, transparent approach to facilitate early review and enhanced communication between study sponsors and scientific reviewers of initial study proposals including RWD.
引用
收藏
页数:12
相关论文
共 38 条
[1]  
21st Century Cures Act. U.S. Food and Drug Administration, ETHICS STATEMENT: Mandatory
[2]  
Ahlbom A, 2021, EUR J EPIDEMIOL, V36, P767, DOI 10.1007/s10654-021-00778-w
[3]   Guidelines for good pharmacoepidemiology practice (GPP) [J].
Andrews, Elizabeth B. ;
Arellano, Felix M. ;
Avorn, Jerry ;
Bortnichak, Edward A. ;
Chen, Robert ;
Dai, Wanju S. ;
de Abajo, Francisco J. ;
Dieck, Gretchen S. ;
de Vries, Corinne ;
Edlavitch, Stanley ;
Freiman, Joel ;
Hallas, Jesper ;
Jones, Judith K. ;
Koo, Linda ;
Kaufman, David W. ;
Kurz, Xavier ;
Lanes, Stephan ;
Mitchell, Allen A. ;
Moride, Yola ;
Nelson, Robert C. ;
Neutel, Ineke ;
Park, Byung-Joo ;
Perez-Gutthann, Susana ;
Reynolds, Robert ;
Sacks, Susan ;
Santanello, Nancy ;
Stang, Paul ;
Stergachis, Andrew ;
Strom, Brian L. ;
Stuermer, Til ;
Toh, Darren ;
Trontell, Anne ;
Walker, Alexander M. ;
Waller, Patrick ;
Watson, Douglas J. ;
West, Suzanne ;
Wilcock, Karen ;
Wise, Robert P. .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 (01) :2-10
[4]  
[Anonymous], 2023, Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products
[5]  
[Anonymous], Adequate and wellcontrolled studies. 21CFR314.126. Code of Federal Regulations
[6]  
[Anonymous], 2016, BEST (Biomarkers, EndpointS, and Other Tools)
[7]  
[Anonymous], Methods guide for medical test reviews Internet
[8]   Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making [J].
Berger, Marc L. ;
Sox, Harold ;
Willke, Richard J. ;
Brixner, Diana L. ;
Eichler, Hans-Georg ;
Goettsch, Wim ;
Madigan, David ;
Makady, Amr ;
Schneeweiss, Sebastian ;
Tarricone, Rosanna ;
Wang, Shirley V. ;
Watkins, John ;
Daniel Mullins, C. .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 (09) :1033-1039
[9]   Assessing the practice of data quality evaluation in a national clinical data research network through a systematic scoping review in the era of real-world data [J].
Bian, Jiang ;
Lyu, Tianchen ;
Loiacono, Alexander ;
Viramontes, Tonatiuh Mendoza ;
Lipori, Gloria ;
Guo, Yi ;
Wu, Yonghui ;
Prosperi, Mattia ;
George, Thomas J., Jr. ;
Harle, Christopher A. ;
Shenkman, Elizabeth A. ;
Hogan, William .
JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 2020, 27 (12) :1999-2010
[10]   The US Food and Drug Administration Sentinel System: a national resource for a learning health system [J].
Brown, Jeffrey S. ;
Mendelsohn, Aaron B. ;
Nam, Young Hee ;
Maro, Judith C. ;
Cocoros, Noelle M. ;
Rodriguez-Watson, Carla ;
Lockhart, Catherine M. ;
Platt, Richard ;
Ball, Robert ;
Dal Pan, Gerald J. ;
Toh, Sengwee .
JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 2022, 29 (12) :2191-2200